[Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease]. [PDF]
Zhonghua Gan Zang Bing Za ZhiWang XY, Sun HM, Gao YH.
europepmc +1 more source
, 2012 本论文以我国最主要的粮食作物水稻为研究对象，从代谢角度出发，围绕植物领域的热点问题--转基因和逆境胁迫进行深入研究。 建立并表征了基于衍生化GC-MS的谷物全组分代谢组学分析方法。优化了代谢物提取体系，为开展全面的水稻代谢组学研究奠定了基础。 开展组织培养与基因插入引起的水稻代谢表型变异研究。GC-MS代谢轮廓方法结合单变量和多变量分析，发现：转基因后，氨基酸、有机酸、糖等发生了显著变化，与插入突变相比，组织培养过程伴随的体细胞变异对表型影响更大。PCA显示回交会使后代的表型趋近于轮回亲本 ...
周佳
core
[White matter microstructural disturbance and its relationship with cognitive function in schizophrenia with comorbidity of metabolic syndrome]. [PDF]
Sheng Wu Yi Xue Gong Cheng Xue Za ZhiZhou J +7 more
europepmc +1 more source
[Burden and epidemiological trends of alcohol use disorder and alcoholic liver disease in the Asia-Pacific region]. [PDF]
Zhonghua Gan Zang Bing Za ZhiZhuang QC, Yang CQ.
europepmc +1 more source
, 2019 构建微生物细胞工厂是化学品、生物能源以及药物分子可持续生产的可行性策略。然而,微生物的代谢复杂、调控严谨,制约着目标产物高效合成。蛋白质组学和代谢组学可以从系统生物学角度分析酶和代谢物组分,从而理解复杂的生物系统,为微生物代谢工程改造提供重要线索。该文介绍了蛋白质组学和代谢组学在微生物代谢工程中的应用,包括基因组尺度代谢模型构建、菌株生物合成优化、指导菌株耐受性改造、限速步骤预测、植物次级代谢途径挖掘,从而为微生物合成天然产物提供新的基因或途径。在此基础上 ...
高教琪, 禹伟, 周雍进
core
[Gut microbiota and allergic diseases]. [PDF]
Zhong Nan Da Xue Xue Bao Yi Xue BanYu L, Wu M, Zheng X.
europepmc +1 more source
[Association between 473 gut microbiota and Alzheimer's disease: a Mendelian randomization mediation analysis of 233 circulating metabolites]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoLi D, Li Y, Yang X, Wang Y, Qu Y.
europepmc +1 more source
[Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity]. [PDF]
Zhonghua Gan Zang Bing Za ZhiGuan JB +8 more
europepmc +1 more source
[Research progress on the applicability of diagnostic criteria for metabolic and alcohol-related liver disease in patients with cirrhosis and after liver transplantation]. [PDF]
Zhonghua Gan Zang Bing Za ZhiHan Y, Xu H, Wang L.
europepmc +1 more source
[Exploration of the mechanisms of portal hypertension driven by metabolic disorders in non-cirrhotic stages of metabolic-associated fatty liver disease]. [PDF]
Zhonghua Gan Zang Bing Za ZhiZhao YQ, Wang Y, Liu JJ, You H, Zhao JJ.
europepmc +1 more source